Central Plains Bancshares 3Q 2026: Revenue $5.56M, EPS $0.3 — 10-Q Summary

Central Plains Bancshares reported 3Q 2026 revenue of $5.56M, up 5.5% YoY, with net income rising 32.2% to $1.17M. Net interest income increased 11.9%, while noninterest income fell 37.4%. Loan and deposit balances grew, and the company reinvested proceeds into higher-yielding securities.

Original reporting
Published Nov 13, 2026, 9:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Central Plains Bancshares 3Q 2026: Revenue $5.56M, EPS $0.3 — 10-Q Summary — source image
Decision brief

The 30-second read

$CPBIBullishMed
01

Why it matters

The earnings beat provides a short‑term catalyst for the stock, but the decline in non‑interest income and modest loan growth suggest limited upside.

02

Market read

Primary earnings disclosure for a micro‑cap bank; modest trading relevance.

03

What to watch

Higher loan growth may increase credit risk exposure; non‑interest income fell sharply, which could weigh on future earnings.

Relevance 6/10Novelty 6/10Timing: after‑hours release

Background

Central Plains Bancshares (CPBI) filed its Q3 2026 10‑Q, reporting modest revenue growth and a significant rise in net income.

Company-level read

Ticker impact

$CPBIBullishHigh confidence
Context

Q3 2026 10‑Q shows revenue $5.56M (+5.5%), net income $1.17M (+32.2%) and EPS $0.30, indicating earnings beat expectations.

Expected impact

likely modest upside as the market prices in stronger earnings and higher net interest income

Evidence & confidence

Revenue and EPS both rose year‑over‑year; net interest margin held steady while loan growth accelerated, suggesting improved profitability.

Market effects

Banking sector may see slight uplift as a regional lender reports stronger loan growth and net interest income.

Mid‑west community banking outlook improves modestly.

Limited; impact confined to U.S. regional banking niche.

Counterpoint

If the earnings beat is already priced in, the stock could face profit‑taking pressure.

Key entities

  • Central Plains Bancshares, Inc.

    Regional bank reporting Q3 2026 results.

Related articles

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.

$YTRAMed

Yatra Online Inc (YTRA) (Q2 2027) Earnings Call Highlights: Air and Corporate Travel

Yatra Online (YTRA) reported Q2 2027 revenue from operations down 39% YoY to INR2,136M (~$22M) due to lower MICE volumes. Gross margin stayed flat at INR1,255M (~$13M). Adjusted EBITDA swung to negative INR32M (~negative $0.3M). CEO Gupta noted MICE recovery signs, TravelPro and Recap initiatives progress, and AI efficiency gains. Standalone hotels grew 20% YoY. H1 FY27 revenue declined 28% YoY to INR4,015M (~$42M).

$PARKHighAI 8/10

Park Dental Partners Inc (PARK) (Q3 2026) Earnings Call Highlights: Revenue Climbs 6%

Park Dental Partners Inc (PARK) reported Q3 2026 revenue of $64.9M, up 6% YoY, driven by acquisitions and clinical hours. The company acquired Village Family Dental for $39.1M, funded with cash, a small credit line draw, and stock. PARK updated its 2026 revenue outlook to $262M-$265M and adjusted EBITDA to $21.2M-$22.2M. Gross margin declined due to higher salaries and cybersecurity costs. The acquisition adds 47 doctors and expands PARK's footprint to North Carolina.